Terminal is the live negotiation environment. Terminal access is restricted to approved users, to request access or you are having trouble logging in, contact firstname.lastname@example.org.
We are 100% focused on helping both pharma and payers get innovative therapies to patients and improving outcomes.
Millions of patients across the globe need these new, innovative therapies to survive, like new generation combination oncology, and gene therapies. The sad truth is that many of these therapies are ready and approved to go to market — they’re just stuck in limbo waiting for an agreement between payers and pharma.
Market access teams in pharma and payers are working diligently to get these therapies to market, but managing deals for them takes a lot of time and resources — especially when there’s more to negotiate than just price. What you need — and what we’ve created — is an infrastructure to make complicated deals possible and scalable.
Negotiate on price, outcomes, performance provisions, combination therapies, multi-indication pricing, and more.
Manage a large volume of deals at scale easily
More patients get the life-saving therapies they both need and deserve.
Founders Nathan Sigworth and Richard Bergström are no strangers to infrastructural roadblocks in pharma. As founder and former CEO of PharmaSecure, Sigworth led the fight against counterfeit drugs in the developing world. Meanwhile, Bergström had spent his career on the frontlines of drug innovation and access across Europe.
Esteemed industry leaders and staunch believers that deal making can be improved, Sigworth and Bergström* assembled a team of experts in pharma, finance, business, and tech — and worked in collaboration with both pharma and payers — to create PharmaCCX’s Contingent Commitment Exchange.
A first of its kind, the Exchange allows pharma and payers to communicate without revealing proprietary information, overcome the administrative bottleneck of mounting complex agreements, and increase market access.
Market access doesn’t need disruption, it needs infrastructure. We’re committed to supporting your important work with the infrastructure to do it as effectively as possible.
Launched in 2018, PharmaCCX is the only all-in-one platform specifically designed to help both pharma and payers negotiate, agree, settle, and manage complex deals.
A health-tech entrepreneur who formerly co-founded and was CEO of PharmaSecure, which uses serialization to prevent counterfeit drugs from entering the global pharmaceutical supply chain.
An operations expert who was formerly Chief of Staff at Formlabs, a 3D printing company, and who spent a decade developing strategy, program and product management for Alarm.com (ALRM), a home security and automation company. Peter is a graduate of Colby College (BA) and Thayer School of Engineering at Dartmouth College (BE, MEM).
A leader in building financial trading systems, Armen led the development of Fixed Income Execution Platform for Charles River IMS and also held development roles at Farallon Capital Management and LifeYield. Armen holds an MS in Computer Science from Armenian State Polytechnic Institute.
Highly respected advisor for life science policy and health technology assessment, and former Executive Director of NICE, the National Institute for Health and Care Excellence.
Leading expert in the science and practice of health technology assessment (HTA). He serves as the Chair of the Health Technology Assessment Council of the Professional Society for Health Economics and Outcomes Research (ISPOR). Dr. O'Rourke was most recently President and CEO at CADTH (2009 - 2020) after a distinguished career as a Pharmacist and Health Care Executive with the Canadian military.
Seasoned pharma executive with 20+ years in the industry. Mel has held leadership positions at Roche, GSK, and Otsuka in both R&D and Commercial divisions. He is currently the Managing Director at BioPharma Futures where he advises companies on enhancing the value of assets during clinical development. He is also a member of NDA Group's Advisory Board and a Strategic Advisor to Eleusis Therapeutics.
Julia current serves as VP, Operations at Thirty Madison. Previously, she was COO at Tempest. She has been a commercial leader at Ginger.io, Beacon Health Options, Institute on Aging, and McKinsey. Julia is a graduate of Stanford GSB and Dartmouth College.
Barath joined Accel in 2012 and has been in the healthcare domain for over a decade, having previously served as a senior consultant at Frost & Sullivan covering healthcare and life sciences. Barath has a bachelor’s degree in Pharmacy from BITS, Pilani and an MBA from Carnegie Mellon University.